Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs Global X NASDAQ 100 Covered Call ETF (QYLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs Global X NASDAQ 100 Covered Call ETF — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.84 (market cap $6.04B), while Global X NASDAQ 100 Covered Call ETF trades at $18.69 (market cap $8.49B). The key difference: Global X NASDAQ 100 Covered Call ETF is the larger of the two by market cap, and Iovance Biotherapeutics Inc. Common Stock is more actively traded (14,805,993 versus 2,913,938). Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and Global X NASDAQ 100 Covered Call ETF for 51 Days on average.
| IOVA | QYLD | |
|---|---|---|
Market Cap | $6.04B | $8.49B |
Volume | 14,805,993 | 2,913,938 |
Sector | Health | Income / Options Overlay |
52-Week High | $14.82 | $18.68 |
52-Week Low | $1.81 | $16.70 |
Typical Hold Time | 0 Days | 51 Days |
Enterprise Value | $5.97B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
QYLD trades at $18.685 with minimal daily movement (+0.03%), showing technical bullish signals from moving averages but bearish oscillator readings including overbought RSI levels. The ETF maintains consistent monthly dividend distributions of $0.18 per share, though recent news highlights concerns about declining option premiums and long-term capital erosion despite the attractive yield.
The outlook remains cautious as covered call strategies limit upside participation during market rallies. While providing reliable income, QYLD faces structural headwinds including capped growth potential and potential tax reclassification of distributions. Investors should weigh the trade-off between high current yield and long-term total return potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About Global X NASDAQ 100 Covered Call ETF
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →
